Area of research
Oncology · Hematology
Research interest
Research interests include CAR-T cell therapy research, Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, and Phagocytosis and Immune Regulation.
A Molecular Glue Approach to Control the Half-Life of CRISPR-Based Technologies
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology
Clonal hematopoiesis is associated with protection from Alzheimer’s disease
Proteolysis-targeting chimeras with reduced off-targets
Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7
Data from Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Clonal Hematopoiesis is Associated with Reduced Risk of Alzheimer's Disease
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis
CD99 identifies disease stem cells in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS)
Abstract 3303: Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia